Vancouver, BC - The PET and Recovery Following Revascularization (PARR-2) trial showed that, among patients with severe left ventricular (LV) dysfunction, those who received fluorodeoxyglucose (FDG) ...
Please provide your email address to receive an email when new articles are posted on . Key risk factors that may predict severe disease in patients with MIS-C include fever greater than 103.1 degrees ...
Please provide your email address to receive an email when new articles are posted on . In patients with severe left ventricular systolic dysfunction on optimal medical therapy for HF, undergoing PCI ...
Patients enrolled in the ISCHEMIA trial with a history of heart failure or left ventricular dysfunction randomized to invasive management with either PCI or CABG surgery had significantly better ...
Background There is a lack of contemporary data describing patients with left ventricular (LV) systolic dysfunction post ...
Percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure hospitalization in patients with severe left ventricular dysfunction and extensive coronary artery disease ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
The study covered in this summary was published in medRxiv.org as a preprint and has not yet been peer-reviewed. Impaired left ventricular (LV) myocardial strain observed in patients with obstructive ...
Background Aortic stenosis (AS) frequently coexists with heart failure (HF), but its prevalence, prognostic impact and management across the full HF spectrum remain incompletely characterised. Methods ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results